SCHEMBL1922410

SCHEMBL1922410

COC(=O)C(Oc1c(C)nn2c(-c3ccc(Cl)cc3Cl)c(C)oc12)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.38
DPP8 Q6V1X1 1/20 0.38
EDNRA P25101 1/20 0.36
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 2/20 0.35
CRHR1 P34998 3/20 0.35
PPARA Q07869 3/20 0.35
PPARG P37231 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CNR1 P21554 2/20 0.35
MAPT P10636 1/20 0.35
LMNA P02545 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
GCGR P47871 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1922743 0.85 DPP4 (0.38) DPP4DPP8ALDH1A1HPGDCRHR1
SCHEMBL1921789 0.85 DPP4 (0.38) DPP4DPP8ALDH1A1HPGDCRHR1
SCHEMBL12360887 0.83 DPP4 (0.38) DPP4DPP8CRHR1CYP3A4CYP2C9
SCHEMBL1922574 0.83 DPP4 (0.38) DPP4DPP8CRHR1CYP3A4CYP2C9
SCHEMBL12360890 0.83 DPP4 (0.38) DPP4DPP8CRHR1CYP3A4CYP2C9
SCHEMBL1923838 0.82 CRHR1 (0.38) DPP4DPP8CRHR1CYP3A4CYP2C9
SCHEMBL2256506 0.78 DPP4 (0.37) DPP4DPP8ALDH1A1HPGDCRHR1
SCHEMBL1922381 0.78 CRHR1 (0.39) DPP4DPP8ALDH1A1KDM4EHPGD
SCHEMBL1922550 0.78 CRHR1 (0.42) DPP4DPP8CRHR1
SCHEMBL2255251 0.77 CRHR1 (0.44) DPP4DPP8CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011529943-A 2011-12-15 JP claimed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 US claimed
EP-2328902-A1 PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS Novartis AG (CH) 2011-06-08 EP claimed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 WO claimed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 US claimed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 US disclosed
EP-2328902-A1 PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS Novartis AG (CH) 2011-06-08 EP disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 WO disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 WO disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035874-A1 Organic compounds CRH, CRHR1, CRHR2 DPP4 958/4885DPP8 593/4885EDNRA 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.